Navigation Links
Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors

INDIANAPOLIS, Aug. 26 /PRNewswire/ -- Semafore Pharmaceuticals Inc. presented data at the Seventh International Congress on Targeted Therapies in Cancer in Washington, D.C., announcing the discovery of novel multi-targeted kinase inhibitors that demonstrate significant anticancer activity in preclinical studies.

A novel and proprietary molecular scaffold has been developed using computational modeling allowing for the design of pan-PI3 kinase inhibitors as well as isoform-selective small molecule PI3 kinase inhibitors. The scaffold also allows for the design of compounds that can be administered orally or intravenously. Of 50 compounds identified, SF2523 and SF2506 have been chosen for additional evaluation based on their ability to inhibit multiple kinases, including PI3K, mTOR, DNA-PK and PIM-1. SF2523 and SF2506 also have dramatically increased potency relative to the well-known PI3 kinase inhibitor LY294002. Both inhibitors demonstrated the ability to significantly induce apoptosis in a renal cell carcinoma cell line (786-0).

Evaluation of SF2523 in a 232 kinase panel screen showed that the compound selectively and potently inhibits key cancer kinase targets, including mTOR, DNA-PK, PIM-1 and PI3K. SF2523 demonstrated potent anticancer proliferation activity across a broad range of 18 cancer cell lines representing solid tumors (lung, pancreatic, prostate, colon, breast, brain, ovarian, renal and melanoma) and hematological malignancies (AML, CML and multiple myeloma). Notably, SF2523 inhibited proliferation in multiple cell lines with KRAS mutations, including HCT116-colon, A549 lung, BXPC3 pancreatic and RPMI8226 myeloma cell lines. Colorectal cancer patients with KRAS mutations have been identified as less likely to respond to EGFR inhibitors (ASCO 08). New compounds with activity against KRAS mutations are being actively pursued to address the unmet medical need.

In vivo testing of SF2523 in renal cell carcinoma (RCC) mouse xenograft models demonstrated 81 percent tumor growth inhibition. SF2506 testing resulted in 93 percent tumor growth reduction in the same model.

"Semafore's proprietary kinase scaffold and our new multi-targeted kinase inhibitors add significant value to our pipeline," said Dr. Dennis McKeever, Semafore's Chief Executive Officer. "In addition to inhibiting all Class I isoforms of PI3K, our compounds SF2506 and SF2523 block additional key kinases which is in keeping with the multi-targeting philosophy behind other recent successful molecularly targeted agents."

About Semafore

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus -- cancer. Semafore is a leader in the development of PI3K inhibitors and one of the first biopharmaceutical companies to focus on both PI3K and PTEN. The company has successfully discovered and is developing a portfolio of drug candidates addressing these targets.

About SF1126

There is a strong and significant biological rationale for developing PI3 kinase inhibitors to treat cancer. Phosphoinositide 3-kinase (PI3K) is the gate keeper of one of the major pathways of intracellular signal transduction that regulates cell growth, proliferation, angiogenesis, migration, differentiation, and survival. Dysregulation of the PI3K signaling pathway is believed to play an integral role in the genesis of many cancers including both solid tumors and hematologic malignancies. Cancer research and pharmaceutical drug development efforts have been aimed at discovering and developing therapeutics that inhibit PI3K with the hope of controlling cancer cell division, angiogenesis (the formation of new blood vessels for cancer growth), proliferation and metastasis. Semafore's innovative PI3K inhibitor, SF1126, promises such hope for cancer patients.

SF1126, is a proprietary small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class I isoforms and other key members of the PI3K superfamily, including mTOR, DNA-PK, PLK-1, CK2, ATM and PIM-1 kinases all known to be involved in the cascade of chemical signals that control cell division. Importantly, SF1126 is designed as a dual inhibitor of both angiogenesis and cell proliferation. SF1126 is engineered to target and bind to specific integrins (alpha gamma beta 3) that are expressed on the surface of new tumor vasculature and within the tumor endothelial compartment. In tumor xenograph models Semafore demonstrated enhanced drug uptake of SF1126 which was directly attributable to the alpha gamma beta 3 targeted moiety. SF1126 is water soluble, has favorable pharmacokinetics and is well tolerated.

SF1126 is currently in Phase I clinical trials in both solid tumors and multiple myeloma.

For more information see the company's Web site at

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
2. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
3. Semafores SF1126 Exhibits Antitumor and Antiangiogenic Activity
4. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
5. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
6. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
7. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
8. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
9. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
10. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
11. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting
Post Your Comments:
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... Cardiac Pacemaker Market Outlook to 2019 - Rise in Cardiac ... " report to their offering. ... Boston scientific and others. --> ... Medtronic, Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Japanese ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced today that ... (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics SL ERP ... partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing commitment ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... Secura Consultants has prided itself for not only fulfilling the needs of advisers ... solutions at an affordable price and providing top-tier customer service. However, there's always ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to ... Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored ... one of twelve colleges and universities in the state of California make the cut. ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and Dr. ... Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial ... conditions present in similar ways and require time-critical intervention to avoid large area heart ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
Breaking Medicine News(10 mins):